These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32509182)

  • 1. In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with
    Li M; Ehlerding EB; Jiang D; Barnhart TE; Chen W; Cao T; Engle JW; Cai W
    Am J Transl Res; 2020; 12(5):1862-1872. PubMed ID: 32509182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
    Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
    Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiolabelling and preclinical characterization of
    Burvenich IJG; Goh YW; Guo N; Gan HK; Rigopoulos A; Cao D; Liu Z; Ackermann U; Wichmann CW; McDonald AF; Huynh N; O'Keefe GJ; Gong SJ; Scott FE; Li L; Geng W; Zutshi A; Lan Y; Scott AM
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3075-3088. PubMed ID: 33608805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immuno-PET Imaging of
    Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
    Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiolabelling and preclinical characterisation of [
    Cao Z; Wichmann CW; Burvenich IJG; Osellame LD; Guo N; Rigopoulos A; O'Keefe GJ; Scott FE; Lorensuhewa N; Lynch KP; Scott AM
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3202-3214. PubMed ID: 38730087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical PET imaging with the novel human antibody
    Kelly MP; Makonnen S; Hickey C; Arnold TC; Giurleo JT; Tavaré R; Danton M; Granados C; Chatterjee I; Dudgeon D; Retter MW; Ma D; Olson WC; Thurston G; Kirshner JR
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
    Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
    J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of
    Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C
    J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
    Li D; Zou S; Cheng S; Song S; Wang P; Zhu X
    Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Jung KH; Park JW; Lee JH; Moon SH; Cho YS; Lee KH
    J Nucl Med; 2021 May; 62(5):656-664. PubMed ID: 32917780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immuno-PET imaging of VEGFR-2 expression in prostate cancer with
    Li M; Jiang D; Barnhart TE; Cao T; Engle JW; Chen W; Cai W
    Am J Cancer Res; 2019; 9(9):2037-2046. PubMed ID: 31598404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ImmunoPET Imaging of CD146 Expression in Malignant Brain Tumors.
    Hernandez R; Sun H; England CG; Valdovinos HF; Barnhart TE; Yang Y; Cai W
    Mol Pharm; 2016 Jul; 13(7):2563-70. PubMed ID: 27280694
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Bridgwater C; Geller A; Hu X; Burlison JA; Zhang HG; Yan J; Guo H
    Cancer Biother Radiopharm; 2020 Oct; 35(8):549-557. PubMed ID: 32315549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cysteine-specific
    Lee JH; Jung KH; Kim M; Lee KH
    Front Immunol; 2022; 13():1017132. PubMed ID: 36591250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET/CT Imaging of
    Li W; Wang Y; Rubins D; Bennacef I; Holahan M; Haley H; Purcell M; Gantert L; Hseih S; Judo M; Seghezzi W; Zhang S; van der Veen EL; Lub-de Hooge MN; de Vries EGE; Evelhoch JL; Klimas M; Hostetler ED
    Mol Imaging Biol; 2021 Apr; 23(2):250-259. PubMed ID: 33104972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive PET imaging of tumor PD-L1 expression with
    Malih S; Lin W; Tang Z; DeLuca MC; Engle JW; Alirezapour B; Cai W; Rasaee MJ
    Am J Nucl Med Mol Imaging; 2024; 14(1):31-40. PubMed ID: 38500749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
    Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probody Therapeutic Design of
    Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M
    Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105.
    Hong H; Severin GW; Yang Y; Engle JW; Zhang Y; Barnhart TE; Liu G; Leigh BR; Nickles RJ; Cai W
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):138-48. PubMed ID: 21909753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.